KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Current Assets: 2014-2024

Historic Current Assets for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Dec 2024 value amounting to $446.6 million.

  • Aurinia Pharmaceuticals' Current Assets fell 0.39% to $438.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $438.7 million, marking a year-over-year decrease of 0.39%. This contributed to the annual value of $446.6 million for FY2024, which is 5.13% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Current Assets of $446.6 million as of FY2024, which was up 5.13% from $424.8 million recorded in FY2023.
  • Aurinia Pharmaceuticals' 5-year Current Assets high stood at $513.3 million for FY2021, and its period low was $419.4 million during FY2020.
  • Its 3-year average for Current Assets is $438.0 million, with a median of $442.5 million in 2022.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 33.09% in 2020, then declined by 13.79% in 2022.
  • Over the past 5 years, Aurinia Pharmaceuticals' Current Assets (Yearly) stood at $419.4 million in 2020, then rose by 22.39% to $513.3 million in 2021, then dropped by 13.79% to $442.5 million in 2022, then dropped by 4.01% to $424.8 million in 2023, then grew by 5.13% to $446.6 million in 2024.